Clovis Oncology Announces Presentations at 2019 ASCO Annual Meeting

San Francisco, CA (UroToday.com) -- Clovis Oncology, Inc. announced that four abstracts featuring data for Rubraca® (rucaparib) and ongoing studies in multiple tumor types will be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 – June 4 in Chicago.

The accepted abstracts summarize clinical trials in which Rubraca is being evaluated as a single agent and as combination therapy with nivolumab in a variety of solid tumor types including ovarian, prostate, biliary tract and endometrial cancers. These include additional genomic profiling data from TRITON2, and new data from extended follow up of patients in ARIEL3.

“Increased understanding about the role of genomic mutations, as well as the growing number and type of oncology therapies, offer tremendous potential for us to more precisely target and improve treatment of the most challenging cancers,” said Patrick J. Mahay, President and CEO of Clovis Oncology.
“In our own clinical development program and in investigator-led studies, we are evaluating the utility of Rubraca in multiple solid tumor types where there is genomic rationale, including among patients with BRCA1/2 mutations as well as mutations in other genes that play a role in DNA repair.”

The two Clovis Oncology-sponsored abstracts accepted for presentation at the 2019 ASCO Annual Meeting comprises:

Abstract 5031 (Poster Board #143) - Genomic characteristics of deleterious BRCA1 and BRCA2 alterations and associations with baseline clinical factors in patients with metastatic castration-resistant prostate cancer enrolled in TRITON2

  • Presenter: Wassim Abida, MD, PhD
  • Session: Genitourinary (Prostate) Cancer
  • Date/Time: Saturday, June 1, 1:15-4:15 p.m. Central Daylight Time (CDT)
  • Location: Hall A
Abstract 5522 (Poster Board #345) - Exploratory analysis of the effect of maintenance rucaparib on post progression outcomes in patients with platinum-sensitive recurrent ovarian carcinoma and updated safety data from the phase 3 study ARIEL3

  • Presenter: Robert L. Coleman, MD, FACOG, FACS
  • Session: Gynecologic Cancer
  • Date/Time: Saturday, June 1, 1:15-4:15 p.m. CDT
  • Location: Hall A
This poster (abstract #5522) will be discussed at the associated poster discussion session on Saturday, June 1, 4:30- 6:00 p.m. CDT in Room S406.

The two Clovis-sponsored posters will be available online at http://clovisoncology.com/pipeline/scienticpresentations/ once they are presented at the meeting.

Additionally, two investigator-sponsored abstracts describing combination studies of Rubraca and nivolumab trials in progress are also being presented:

Abstract TPS2663 (Poster Board #297b) - A phase Ib/IIa study of rucaparib (PARP inhibitor) combined with nivolumab in metastatic castrate-resistant prostate cancer and advanced/recurrent endometrial cancer

  • Presenter: Raanan Alter, MD
  • Session: Developmental Immunotherapy and Tumor Immunobiology
  • Date/Time: Saturday, June 1, 8:00-11:00 a.m. CDT
  • Location: Hall A
Abstract TPS4153 (Poster Board #252a) - A multi-center phase II trial of rucaparib in combination with nivolumab as maintenance therapy for patients with advanced biliary tract cancer

  • Presenter: Vaibhav Sahai, MD
  • Session: Gastrointestinal (Noncolorectal) Cancer
  • Date/Time: Monday, June 3, 8:00-11:00 a.m. CDT
  • Location: Hall A


Further Related Content:
 2019 Annual Meeting American Society Of Clinical Oncology (ASCO 2019) Conference Highlights Coming Soon!